MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Home・Akciju saraksts・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

50.47 -1.1

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

50.29

Max

50.62

Galvenie mērījumi
By Trading Economics
Ienākumi	6.6M -39M
Pārdošana	19M 212M
P/E Sektora vidējais	48.435 56.063
EPS	0.882
Peļņas marža	-18.221
Darbinieki	778
EBITDA	127M 90M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+24.8% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-65M 2.8B
Iepriekšējā atvēršanas cena	51.57
Iepriekšējā slēgšanas cena	50.47

Ziņu noskaņojums

By Acuity

56%

44%

296 / 349 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

31.35 / 32.36 Atbalsts un pretestība

Supernus Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. apr. 04:27 UTC

Galvenie ziņu notikumi

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

2026. g. 3. apr. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 3. apr. 18:30 UTC

Galvenie ziņu notikumi

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

2026. g. 3. apr. 18:14 UTC

Tirgus saruna

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

2026. g. 3. apr. 17:50 UTC

Tirgus saruna

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

2026. g. 3. apr. 17:44 UTC

Iegādes, apvienošanās, pārņemšana

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

2026. g. 3. apr. 16:50 UTC

Galvenie ziņu notikumi

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

2026. g. 3. apr. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 3. apr. 16:12 UTC

Peļņas

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

2026. g. 3. apr. 15:56 UTC

Tirgus saruna

Galvenie ziņu notikumi

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

2026. g. 3. apr. 15:56 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Equities Roundup: Market Talk

2026. g. 3. apr. 15:56 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 3. apr. 15:20 UTC

Galvenie ziņu notikumi

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

2026. g. 3. apr. 15:08 UTC

Iegādes, apvienošanās, pārņemšana

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

2026. g. 3. apr. 14:11 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

2026. g. 3. apr. 12:56 UTC

Tirgus saruna

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

2026. g. 3. apr. 08:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 3. apr. 08:01 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 3. apr. 08:01 UTC

Tirgus saruna

Meituan's Profitability Likely to Improve This Year -- Market Talk

2026. g. 3. apr. 07:45 UTC

Tirgus saruna

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

2026. g. 3. apr. 06:17 UTC

Tirgus saruna

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

2026. g. 3. apr. 06:17 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 3. apr. 04:33 UTC

Tirgus saruna

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

2026. g. 3. apr. 04:33 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 3. apr. 04:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 3. apr. 04:01 UTC

Tirgus saruna

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

2026. g. 3. apr. 02:01 UTC

Tirgus saruna

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

2026. g. 3. apr. 01:59 UTC

Tirgus saruna

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

2026. g. 3. apr. 01:44 UTC

Tirgus saruna

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

2026. g. 3. apr. 01:22 UTC

Tirgus saruna

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Salīdzinājums

Cenas izmaiņa

Supernus Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

24.8% augšup

Prognoze 12 mēnešiem

Vidējais 63 USD 24.8%

Augstākais 65 USD

Zemākais 55 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

31.35 / 32.36Atbalsts un pretestība

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Noskaņojums

By Acuity

296 / 349 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.